Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | HTL0039732 |
| Synonyms | |
| Therapy Description |
HTL0039732 is an antagonist of the prostaglandin E2 receptor 4 (EP4), which potentially enhances anti-tumor immune response (Ann Oncol (2024) 35 (Suppl_2): S529-S530). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| HTL0039732 | HTL-0039732|HTL 0039732 | HTL0039732 is an antagonist of the prostaglandin E2 receptor 4 (EP4), which potentially enhances anti-tumor immune response (Ann Oncol (2024) 35 (Suppl_2): S529-S530). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05944237 | Phase Ib/II | Atezolizumab + HTL0039732 HTL0039732 | HTL0039732 in Participants With Advanced Solid Tumours | Recruiting | GBR | 0 |